InterCure (NASDAQ:INCR) Stock Price Down 0.2% – Time to Sell?

InterCure Ltd. (NASDAQ:INCR) shares fell 0.2% on Thursday . The stock traded as low as $5.23 and last traded at $5.24. 5,220 shares were traded during mid-day trading, a decline of 88% from the average session volume of 44,050 shares. The stock had previously closed at $5.25.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of InterCure from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

InterCure Stock Down 1.5%

The firm has a market capitalization of $56.45 million, a P/E ratio of 34.40 and a beta of 1.42. The firm’s 50-day moving average is $4.97 and its 200 day moving average is $4.56. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.97 and a current ratio of 1.48.

InterCure Company Profile

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.